Pediatric Antimicrobial Dosing at Benioff Children's Hospitals (PDF Version)

 

UCSF Benioff Children’s Hospitals

Antimicrobial Dosing Guideline for Infants and Children > 1 Month of Age

Approved by Pharmacy and Therapeutics Committee (11/98) Last Update 4/2025

 

Antimicrobial Stewardship Program

(ASP)

M-F 8:00 am to 4:30 pm for focused questions on antimicrobial selection, dose, monitoring, duration of therapy and for approvals (Voalte: Pediatric Antimicrobial Stewardship Team - ID/ASP Pharmacist or Provider)

Oak/SF: Contact via Voalte

Pediatric ID Consult Service

For cases requiring in depth review and physician consultation

 

Online Resources

Pediatric Empiric Antimicrobial Therapy Guidelines, Clinical Pathways, Detailed Guidelines, Antimicrobial Susceptibility Profiles

idmp.ucsf.edu

Shaded boxes indicate ID-Restricted agents (ID-R). Other restricted agents are noted in APeX.

An approving clinician’s ID number is needed to order a restricted agent. To obtain approval for a restricted agent,

call Pediatric ASP between 8:30 am to 5:00 pm M-F. For off-hours approval (until 9:00 pm) contact the Pediatric ID Consult Service. From 9:00 pm to 8:00 am, use approval ID# 11111 for release of a single dose, then contact ASP for approval of subsequent doses.

 

For infants with renal dysfunction please use the neonatal antibiotic renal dosing reference

Dosing recommendations are for usual doses to treat the most common conditions.

For additional indication-specific dosing, or agents not included below, refer to the

Pediatric Empiric Antimicrobial Therapy Guidelines (EATG) (idmp.ucsf.edu), or Lexi-Comp.

Consult pharmacist or Lexidrug for renal dose adjustment.

For dosing in patients with Cystic Fibrosis (CF)

CKD EPI calculator     CKiD U25 calculator

Drug

Usual Dose

Dose Adjustment

Maximum Dose

Acyclovir IV

 

Note: Use adjusted body weight for dosing in patients with obesity

 

Mucocutaneous HSV Infection

Immunocompetent Host ≥ 3 mo

5 mg/kg/dose q8h

 

CNS HSV Infection >= 3 mo to < 12 yo

15 mg/kg/dose q8h

 

CNS HSV >= 12 yo,

HSV in Immunocompromised Host, or VZV Infection

10 mg/kg/dose q8h

 

HSV Infection < 3 mo

20 mg/kg/dose q8h

 Adjust for

CrCl < 50 ml/min/1.73m2

Usual Max

1000 mg/dose

Acyclovir PO preferred for non-invasive infection in immunocompetent host > 3 months old – refer to Pediatric EATG or Lexi-Comp for dose

Amphotericin B

Liposomal IV ID-R

(Ambisome®)

5 mg/kg/dose q24h

No recommended dose adjustment for renal dysfunction, but drug should be used with caution due to nephrotoxicity risk

None

Ampicillin IV

50 mg/kg/dose q6h

Endocarditis, Meningitis:

400 mg/kg/day divided q4h to q6h

Adjust for

CrCl < 50 ml/min/1.73m2

 

2000 mg/dose

 

Ampicillin-

sulbactam IV

(Unasyn®)

50 mg ampicillin/kg/dose q6h

Adjust for

CrCl < 30 ml/min/1.73m2

Usual Max

2000 mg ampicillin/dose

Amoxicillin PO

22.5 mg/kg/dose bid

 

High Dose (Pneumococcal)

45 mg/kg/dose bid

 

Strep pharyngitis:

50 mg/kg/dose qday

Adjust for

CrCl < 30 ml/min/1.73m2

Usual Max

1000 mg/dose

Amoxicillin-clavulanate PO

(Augmentin®)

< 3 mo: 15 mg amox/kg/dose bid

(Use 250 mg/5 mL suspension)

 

Standard Dose >= 3 mo

22.5 mg amox/kg/dose bid

 

High Dose (Pneumococcal) >= 3 mo

45 mg amox/kg/dose bid

 

Adjust for

CrCl < 30 ml/min/1.73m2

Usual Max

Susp: 840 mg/dose or 880 mg/dose depending on concentration

Tablet: 875 mg/dose bid

 

 

 

Cefazolin IV

Mild-Moderate Infection

25 mg/kg/dose q8h

 

Severe Infection

50 mg/kg/dose q8h

Adjust for

CrCl < 50 ml/min/1.73m2

Mild-Moderate

1000 mg/dose

 

Severe

2000 mg/dose

Cephalexin PO

Mild-Moderate Infection

25 mg/kg/dose tid

 

Severe Infection

e.g. osteomyelitis/pyelonephritis

50 mg/kg/dose tid

Adjust for

CrCl < 50 ml/min/1.73m2

Mild-Moderate

500 mg/dose

 

Severe

1000 mg/dose

Cefepime IV

 

50 mg/kg/dose q8h

 

Adjust for

CrCl < 60 ml/min/1.73m2

 

2000 mg/dose

 

Ceftazidime IV

 

50 mg/kg/dose q8h

 

Adjust for

CrCl < 50 ml/min/1.73m2

 

2000 mg/dose

 

 

Ceftriaxone IV

50 mg/kg/dose q24h

 

Meningitis

50 mg/kg/dose q12h

No adjustment

2000 mg/dose

Ciprofloxacin IV/PO

 

 

Enteral: 15 mg/kg/dose enterally bid

IV: 10 mg/kg/dose IV q8h

 

 

Adjust for

CrCl < 30 ml/min/1.73m2

750 mg enterally bid

400 mg IV q8h

 

 

Clindamycin IV/PO

10 mg/kg/dose q8h

 

Bone/Joint Infection

13 mg/kg/dose q8h

No adjustment

 

Usual max

Enteral: 600 mg/dose

 

IV: 600 mg dose

IV necrotizing fasciitis: 900 mg/dose

 

Fluconazole IV/PO

Invasive Candidiasis

12 mg/kg/dose q24h

Adjust for

CrCl < 50 ml/min/1.73m2

Usual max

800 mg q24h

Varies by site and severity

Gentamicin IV

 

 Note: Use adjusted body weight for dosing in patients with obesity

 

 

 

Monitoring:  

Oak: contact pharm for dosing adjustments 

SF: dosing per pharm 

 

Synergy: 3 mg/kg/dose IV q24h

 

Treatment < 3 mo OR < 52 weeks PMA:

5 mg/kg/dose IV q24h

 

Treatment >= 3 mo AND >= 52 weeks PMA: 7 mg/kg/dose IV q24h

 

 

Adjust for

CrCl < 50 ml/min/1.73m2

Usual Max

1000 mg/dose

Levofloxacin IV/PO

6 mo to < 5 yo: 10 mg/kg/dose q12h

 

>= 5 yo: 10 mg/kg/dose q24h

Adjust for

CrCl < 30 ml/min/1.73m2

750 mg/dose

Meropenem IV

20 mg/kg/dose q8h

Meningitis

40 mg/kg/dose q8h

Adjust for

CrCl < 50 ml/min/1.73m2

2000 mg/dose

Metronidazole IV/PO

10 mg/kg/dose q8h

 

Appendicitis

30 mg/kg/dose q24h

Adjust for

CrCl < 10 ml/min/1.73m2

500 mg/dose

 

Appendicitis

1500 mg/dose

Nafcillin or Oxacillin IV

50 mg/kg/dose q6h

Adjust for concurrent hepatic and renal dysfunction

Individual Dose

2000 mg/DOSE

Daily Dose

12,000 mg/DAY

Penicillin G IV (aqueous)

Mild-Moderate Infection

200,000 units/kg/day divided q4h

 

Severe Infection

eg endocarditis, meningitis

400,000 units/kg/day divided q4h

Adjust for

CrCl < 10 ml/min/1.73m2

 

4 million units/dose

Piperacillin/

Tazobactam IV (Zosyn®)

100 mg piperacillin/kg/dose q6h

Adjust for

CrCl < 40 ml/min/1.73m2

4000 mg piperacillin/dose

Tobramycin IV

 

Note: Use adjusted body weight for dosing in patients with obesity

 

 

 

Monitoring:  

Oak: contact pharm for dosing adjustments 

SF: dosing per pharm 

 

Treatment < 3 mo OR < 52 weeks PMA:

5 mg/kg/dose IV q24h

 

Treatment >= 3 mo AND >= 52 weeks PMA: 7 mg/kg/dose IV q24h

 

Adjust for

CrCl < 50 ml/min/1.73m2

None

TMP/SMX IV/PO

 (Bactrim®, Septra®)

Mild to Moderate Infection

5 mg/kg/dose TMP bid

 

Serious Infection/PCP

5 mg/kg/dose TMP q6h to q8h

Adjust for

CrCl < 30 ml/min/1.73m2

Mild-Moderate

160 mg TMP/dose

 

 

Severe

Enteral: 320 mg TMP/dose

IV: 480 mg TMP/dose

 

Vancomycin IV

 

Oak: contact pharm for dosing adjustments 

 

SF: dosing per pharm 

 

< 1 mo: Refer to Neonatal Dosing Guidelines

1 mo to < 3 mo (PMA 45 weeks to <= 52 weeks): 15 mg/kg/dose IV q8h

>= 3 mo to < 12 yo: 17.5 mg/kg/dose IV q6h

>= 12 yo to < 15 yo: 15 mg/kg/dose IV q6h

>= 15 yo: 15 mg/kg/dose IV q8h

 

CICU/cardiac dysfunction initial dosing:

< 6 months: q12h; >= 6 months: q8h

 

Initial Max

1000 mg/dose

Voriconazole IV/PO

ID-R

 

Empiric dosing if unknown pharmacogenomics (PGx):

< 12 yo

10 mg/kg/dose enterally/IV bid

>= 12 yo

6 mg/kg/dose enterally/IV bid

 

 

Empiric dosing if known PGx

 

No adjustment for renal dysfunction but avoid IV formulation if

CrCl < 50 ml/min/1.73m2

 

Avoid if severe hepatic dysfunction

Initial Max:

400 mg/dose

 

 

Antibiotics in patients with Cystic Fibrosis (CF)

(If patient not responding on appropriate therapy, consider consulting ASP)

 

Drug 

Suggested Dose 

Usual Max Dose 

Other Information 

Pseudomonas (usually 2 antipseudomonal agents):  Tobramycin + Ceftazidime 

  

Pseudomonas + MSSA : Tobramycin + Cefepime 

 

Amikacin

30 mg/kg/dose IV q24h

Consider avoiding doses > 35 mg/kg/day

Requires Therapeutic Drug Monitoring

Peak range: 35 to 45 mcg/mL

Trough: < 5 mcg/mL

Aztreonam

50 mg/kg/dose IV q6h

2000 mg IV q6h

 

Cefepime

50 mg/kg/dose IV q8h

2000 mg IV q8h

 

Ceftazidime

50 mg/kg/dose IV q8h

2000 mg IV q8h

 

Ciprofloxacin

10 mg/kg/dose IV q8h

400 mg IV q8h

 

Piperacillin/Tazobactam (Zosyn®)

100 mg/kg/dose (piperacillin component) IV q6h

4000 mg (piperacillin component) IV q6h

 

Meropenem

40 mg/kg/dose IV q8h

2000 mg IV q8h

 

Tobramycin 

10 mg/kg/dose IV q24h 

Consider avoiding doses >15 mg/kg/dose

Requires Therapeutic Drug Monitoring  

Peak range: 20 to 35 mcg/mL 

Trough: < 1 mcg/mL 

Stenotrophomonas maltophilia:

 

TMP/SMX IV/PO

 (Bactrim®, Septra®)

5 mg/kg/dose (TMP component) IV/PO tid/q8h 

Enteral: 320 mg TMP/dose

IV: 480 mg TMP/dose

Oral route preferred, if possible 

Staphylococcus aureus: The role of staph including MRSA is difficult to assess when a patient is also infected with pseudomonas, but it is often treated if present on recent or current cultures. 

Cefazolin 

50 mg/kg/dose IV q8h

 2000 mg IV q8h

 

Doxycycline 

5 mg/kg/day IV/PO bid/q12h 

200 mg IV/PO bid/q12h 

Oral route preferred, if possible 

TMP/SMX IV/PO

 (Bactrim®, Septra®)

5 mg/kg/dose (TMP component) IV/PO tid/q8h 

Enteral: 320 mg TMP/dose

IV: 480 mg TMP/dose

 

Oral route preferred, if possible 

Vancomycin (Reserved for MRSA) 

 

Oak: contact pharm for dosing adjustments 

 

SF: dosing per pharm 

3 mo to < 12 yo: 17.5 mg/kg/dose IV q6h

 

>= 12 yo to < 15 yo: 15 mg/kg/dose IV q6h

 

>= 15 yo:

15 mg/kg/dose IV q8h

Initial Max

1000 mg/dose

Requires Therapeutic Drug Monitoring 

 

 

 

 

 

G.) Antibiotic Therapeutic Drug Monitoring:

Tobramycin

 

Extended-interval Dosing:  Obtain post dose serum concentrations after the 1st dose 

Renal Function 

When to obtain level  

After which dose? 

CrCl > 50 or CRRT 

Post dose levels 2 and 6 hours after end of infusion 

1st dose 

CrCl < 50 

Post dose levels 2 and 12 hours after end of infusion 

1st dose 

HD or PD 

Level obtained prior to the hemodialysis treatment is recommended to guide dosing 

1st dose